Measurement of the pp(-)-> W gamma plus X cross section at root s=1.96 TeV and WW gamma anomalous coupling limits

The WWγ triple gauge boson coupling parameters are studied using pp̄rarr; νγ+X(=e,μ) events at s=1.96 TeV. The data were collected with the D0 detector from an integrated luminosity of 162pb-1 delivered by the Fermilab Tevatron Collider. The cross section times branching fraction for pp̄→W(γ)+X→ νγ+X with ETγ>8 GeV and ΔR γ> 0.7 is 14.8±1.6(stat)±1.0(syst) ±1.0(lum)pb. The one-dimensional 95% confidence level limits on anomalous couplings are -0.88<Δκγ<0.96 and -0. 20<λγ<0.20. © 2005 The American Physical Society.

First study of the radiation-amplitude zero in W gamma production and limits on anomalous WW gamma couplings at root s=1.96 TeV

We present results from a study of pp̄→Wγ+X events utilizing data corresponding to 0.7fb-1 of integrated luminosity at s=1.96TeV collected by the D0 detector at the Fermilab Tevatron Collider. We set limits on anomalous WWγ couplings at the 95% C.L. The one-dimensional 95% C.L. limits are 0.49<κγ<1.51 and -0.12<λγ<0.13. We make the first study of the charge-signed rapidity difference between the lepton and the photon and find it to be indicative of the standard model radiation-amplitude zero in the Wγ system. © 2008 The American Physical Society.

Measurement of the W boson mass with the D0 detector

We present a measurement of the W boson mass using data corresponding to 4.3fb -1 of integrated luminosity collected with the D0 detector during Run II at the Fermilab Tevatron pp̄ collider. With a sample of 1677394 W→eν candidate events, we measure M W=80.367±0. 026GeV. This result is combined with an earlier D0 result determined using an independent Run II data sample, corresponding to 1fb -1 of integrated luminosity, to yield M W=80.375±0.023GeV. © 2012 American Physical Society.

Combination of CDF and D0 measurements of the W boson helicity in top quark decays

We report the combination of recent measurements of the helicity of the W boson from top quark decay by the CDF and D0 collaborations, based on data samples corresponding to integrated luminosities of 2.7-5.4fb -1 of pp̄ collisions collected during Run II of the Fermilab Tevatron collider. Combining measurements that simultaneously determine the fractions of W bosons with longitudinal (f 0) and right-handed (f +) helicities, we find f 0=0.722±0.081[±0.062(stat)±0.052(syst)] and f +=-0.033±0.046[±0.034(stat)±0.031(syst)]. Combining measurements where one of the helicity fractions is fixed to the value expected in the standard model, we find f 0=0.682±0. 057[±0.035(stat)±0.046(syst)] for fixed f + and f +=-0.015±0.035[±0.018(stat)±0.030(syst)] for fixed f 0. The results are consistent with standard model expectations. © 2012 American Physical Society.

Cohomologia de grupos e invariante algébricos

Pós-graduação em Matemática - IBILCE

Measurement of the p(p)over-bar -> W plus b plus X production cross section at root s=1.96 TeV D0 Collaboration

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Measurement of the W+ W- cross section in sqrt(s) = 7 TeV pp collisions with ATLAS

This Letter presents a measurement of the W+ W- production cross section in sqrt(s) = 7  TeV pp collisions by the ATLAS experiment, using 34  pb(-1) of integrated luminosity produced by the Large Hadron Collider at CERN. Selecting events with two isolated leptons, each either an electron or a muon, 8 candidate events are observed with an expected background of 1.7 ± 0.6 events. The measured cross section is 41(-16)(+20)(stat) ± 5(syst)±1(lumi)  pb, which is consistent with the standard model prediction of 44 ± 3  pb calculated at next-to-leading order in QCD.

Organization of G Proteins and Adenylyl Cyclase at the Plasma Membrane

There is mounting evidence for the organization and compartmentation of signaling molecules at the plasma membrane. We find that hormone-sensitive adenylyl cyclase activity is enriched in a subset of regulatory G protein-containing fractions of the plasma membrane. These subfractions resemble, in low buoyant density, structures of the plasma membrane termed caveolae. Immunofluorescence experiments revealed a punctate pattern of G protein α and β subunits, consistent with concentration of these proteins at distinct sites on the plasma membrane. Partial coincidence of localization of G protein α subunits with caveolin (a marker for caveolae) was observed by double immunofluorescence. Results of immunogold electron microscopy suggest that some G protein is associated with invaginated caveolae, but most of the protein resides in irregular structures of the plasma membrane that could not be identified morphologically. Because regulated adenylyl cyclase activity is present in low-density subfractions of plasma membrane from a cell type (S49 lymphoma) that does not express caveolin, this protein is not required for organization of the adenylyl cyclase system. The data suggest that hormone-sensitive adenylyl cyclase systems are localized in a specialized subdomain of the plasma membrane that may optimize the efficiency and fidelity of signal transduction.

Pisma polityczne z czasów rokoszu Zebrzydowskiego, 1606-1608.

"Pieśń rokoszen z r. 1606" (for discantus 1, discantus 2, altus tenor 1, tenor 2, and bassus, in score): v. 1, p. [377]-384.

Rezydenci napoleońscy w Warszawie 1807-1813.

"Korespondencya Serry z Bourgoingiem. Memoryały Serry. Raporty i depesze" (in French): p. [307]-349.

John Dunlop's Geschichte der prosadichtungen oder geschichte der romane, novellen, märchen u. s. w. ; aus dem englischen übertragen und vielfach verm. und berichtigt, so wie mit einleitender vorrede /

Mode of access: Internet.

Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis

Objective: A secondary analysis of a previously conducted one year randomised controlled trial to evaluate the capacity of responder criteria based on the WOMAC index to detect between treatment group differences. Methods: 255 patients with knee osteoarthritis were randomised to appropriate care with hylan G-F 20'' (AC+H) or appropriate care without hylan G-F 20'' (AC). In the original analysis, two definitions of patient response from baseline to month 12 were used: ( 1) at least a 20% reduction in WOMAC pain score ( WOMAC 20P); ( 2) at least a 20% reduction in WOMAC pain score and at least a 20% reduction in either WOMAC function or stiffness score ( WOMAC 20PFS). For this analysis, a responder was identified using 50% and 70% minimum clinically important response levels to investigate how increasing response affects the ability to detect treatment group differences. Results: The hylan G- F 20 group had numerically more responders using all patient responder criteria. Increasing the response level from 20% to 50% detected similar differences between treatment groups (25% to 29%). Increasing the response level to 70% reduced the differences between treatment groups (11% to 12%) to a point where the differences were not significant after Bonferroni adjustment. Conclusions: These results provide evidence for incorporating response levels ( WOMAC 50) in clinical trials. While differences at the highest threshold ( WOMAC 70) were not statistically detectable, an appropriately powered study may be capable of detecting differences even at this very high level of improvement.

Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis

Objective: To compare the effectiveness and safety of repeat treatment with hylan G-F 20 based on data from a randomized, controlled trial [Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002;10:506-17]. The hypotheses tested were whether the single-course and repeat-course subgroups would be superior to appropriate care and not different from each other. Method: A total of 255 patients with knee osteoarthritis were randomized to appropriate care with hylan G-F 20 or appropriate care without hylan G-F 20. The hylan G-F 20 group was partitioned into two subgroups: (1) patients who received a single course of hylan G-F 20; and (2) patients who received two or more courses of hylan G-F 20. Results: For the primary effectiveness measure, change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score as a percent of baseline, the single-course subgroup improved by 41%, the repeat-course subgroup by 35%, and the appropriate care group by 14%. Both subgroups improved significantly more than the appropriate care group (P < 0.05), and were not statistically significantly different from each other (70% power to detect a 20% difference). Secondary effectiveness measures showed similar results. In the repeat-course subgroup, no statistically significant differences were found in the number of local adverse events, the number of patients with local adverse events, or arthrocentesis rates between the first and repeat courses of treatment. Conclusions: Although the study was neither designed nor powered to examine repeat treatment, this a posteriori analysis provides support for a favorable effectiveness and safety profile of hylan G-F 20 in repeat course patients. (C) 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.